- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07651436
Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients (IDE-3D)
Hemodialysis is a vital replacement therapy for patients with end-stage chronic kidney disease, but it imposes a heavy, demanding, and prolonged management, associated with a significant deterioration in quality of life. Hemodialysis patients are exposed to numerous physical, organizational, and social constraints, including repeated and prolonged sessions at the center, dietary and fluid restrictions, chronic fatigue, and frequent comorbidities. Therefore, depressive disorders in hemodialysis patients represent a major public health issue.
The literature reports a high prevalence of depressive symptoms among hemodialysis patients, ranging from 22% to 60%, significantly higher than that observed in the general population. These disorders are associated with a significant deterioration in quality of life, increased hospitalizations, lower therapeutic adherence, an increased risk of suicide, and excess mortality. Despite these important clinical consequences, depressive disorders often remain underdiagnosed in hemodialysis.
Current guidelines, including those from the Haute Autorité de Santé (HAS), emphasize the importance of regular quality of life assessments in patients with chronic kidney disease and recommend the use of validated questionnaires. However, they do not formalize a specific operational strategy for screening depressive disorders in routine hemodialysis practice, contributing to their under-evaluation.
The gold standard diagnosis of depressive disorders relies on a structured psychiatric interview, which is difficult to reconcile with the organizational constraints of dialysis centers. Standardized self-assessment tools, such as the Hospital Anxiety and Depression Scale (HADS), particularly its depression subscale (HADS-D), have been widely used. The HADS-D has the advantage of excluding somatic symptoms and has been validated in hemodialysis patients.
However, self-assessment relies on the patient's ability to express their subjective experience. Thus, the self-administration of standardized questionnaires in these patients is often challenging due to their age, comorbidities, fatigue, and functional limitations, often necessitating the intervention of healthcare staff. In contrast, registered nurses (IDE) working in hemodialysis possess longitudinal clinical knowledge of patients, acquired over repeated sessions, which can serve as a relevant lever for rapid and standardized screening of depressive symptoms. To date, the diagnostic performance of structured nursing hetero-evaluation remains poorly documented.
The IDE-3D study aims to evaluate the ability of nurses to identify depressive symptoms in hemodialysis patients using structured tools, comparing the nursing hetero-evaluation of the HADS-D with the self-assessment conducted by the patient. It is part of a pragmatic approach aimed at improving the screening of depressive disorders in hemodialysis, structuring the care pathway, and enhancing the integration of mental health into the overall management of hemodialysis patients.
Studieoversigt
Status
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Alexandra Rippoz
- Telefonnummer: 0033 4 85522120
- E-mail: arippoz@ch-annecygenevois.fr
Undersøgelse Kontakt Backup
- Navn: DRCI CH Annecy Genevois
- E-mail: drci.promotion@ch-annecygenevois.fr
Studiesteder
-
-
-
Annecy, Frankrig, 74370
- Centre Hospitalier Annecy Genevois
-
Kontakt:
- Cécile Herlet
- Telefonnummer: 00 33 4 50 58 56 93
- E-mail: cherlet@ch-annecygenevois.fr
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Patient informed about the nature, process, and objectives of the study and having signed a free and informed consent to participate,
- Patient treated with conventional hemodialysis for at least 3 months and currently undergoing dialysis 3 times a week,
- Patient covered by the french national social welfare
Exclusion Criteria:
- Patient suffering from dementia
- Pregnant or breastfeeding patient
- Patient unable to understand the French language both orally and in writing, - making self-assessment impossible
- Patient currently participating in another interventional research protocol or in an exclusion period from such research
- Patient who has already been included in this study
- Patient under guardianship, curatorship, or placed under judicial protection.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: The study is based on conducting parallel and independent assessments for the same patient.
The only intervention will resulting from the research consists of informing the responsible physician of the patient with an HADS-Depression score ≥ 8 to conduct a complementary clinical assessment and determine the appropriate management, according to the procedures in place at each center.
|
Interventional study with minimal risks and constraints.
The main objective is to evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses in patients receiving in-center hemodialysis, compared to reference self-assessment tools completed by the patients.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The diagnostic performance of the hetero-assessment
Tidsramme: Rrom enrollment to the end of intervention (between one week and 2 weeks)
|
For each patient, two HADS-Depression scores will be collected: One score resulting from the hetero-assessment performed by a nurse responsible for the patient, by filling out the 7 items of the depression subscale of the HADS, completed independently and autonomously, blind to the patient's responses, One score resulting from the self-assessment conducted by the patient, by completing the entire HADS questionnaire, considered as the reference method and completed blind to the nurse's responses. The diagnostic performance of the hetero-assessment by the nurse will be evaluated in terms of sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV). |
Rrom enrollment to the end of intervention (between one week and 2 weeks)
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Cécile Herlet, Centre Hospitalier Annecy Genevois
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 24-09
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Depressive lidelser
-
Sheba Medical CenterIkke rekrutterer endnu
-
Aalborg University HospitalRekrutteringDepressiv lidelse | Depression | Depressiv episode | Depressive lidelser | Depressive episoder | Depression - svær depressiv lidelse | Depressiv lidelse, svær depressiv lidelseDanmark
-
Stanford UniversityNational Institute of Mental Health (NIMH)RekrutteringStørre depressiv lidelseForenede Stater
-
TakedaRekrutteringStørre depressiv lidelseJapan
-
Neurocrine BiosciencesRekrutteringStørre depressiv lidelseSpanien, Serbien, Forenede Stater, Bulgarien, Canada, Estland, Italien, Polen, Taiwan, Australien, Sydkorea
-
Luye Pharma Group Ltd.Tilmelding efter invitation
-
NeuroQore Inc.Makromed Inc.Tilmelding efter invitationStørre depressiv lidelseForenede Stater
-
Stanford UniversityNational Institute of Mental Health (NIMH)Ikke rekrutterer endnuStørre depressiv lidelse | Behandlingsresistent depressionForenede Stater
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Canadian... og andre samarbejdspartnereIkke rekrutterer endnuStørre depressiv lidelse | Behandlingsresistent depressionCanada
-
Polytechnic Institute of PortoHospital de Sao Joao, PortoIkke rekrutterer endnuBehandlingsresistent depression | Depression - svær depressiv lidelse